Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.37 |
| ▸ | PSMB8 | P28062 | 12/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 9/20 | 0.36 |
| ▸ | PSMB2 | P49721 | 8/20 | 0.36 |
| ▸ | PSMB1 | P20618 | 7/20 | 0.36 |
| ▸ | PSMB9 | P28065 | 7/20 | 0.36 |
| ▸ | PSMB10 | P40306 | 7/20 | 0.36 |
| ▸ | PSMB11 | A5LHX3 | 6/20 | 0.36 |
| ▸ | PSMA7 | O14818 | 6/20 | 0.36 |
| ▸ | PSMA1 | P25786 | 6/20 | 0.36 |
| ▸ | PSMA2 | P25787 | 6/20 | 0.36 |
| ▸ | PSMA3 | P25788 | 6/20 | 0.36 |
| ▸ | PSMA4 | P25789 | 6/20 | 0.36 |
| ▸ | PSMA5 | P28066 | 6/20 | 0.36 |
| ▸ | PSMB4 | P28070 | 6/20 | 0.36 |
| ▸ | PSMB6 | P28072 | 6/20 | 0.36 |
| ▸ | PSMB3 | P49720 | 6/20 | 0.36 |
| ▸ | PSMA6 | P60900 | 6/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13932374 | 1.00 | SLC7A5 (0.47) | SLC7A5SLC1A3SLC1A2PSMB8PSMB5 | |
| SCHEMBL8269958 | 1.00 | SLC7A5 (0.47) | SLC7A5SLC1A3SLC1A2PSMB8PSMB5 | |
| SCHEMBL20825507 | 1.00 | SLC7A5 (0.47) | SLC7A5SLC1A3SLC1A2PSMB8PSMB5 | |
| SCHEMBL8071092 | 1.00 | SLC7A5 (0.47) | SLC7A5SLC1A3SLC1A2PSMB8PSMB5 | |
| SCHEMBL8082505 | 1.00 | SLC7A5 (0.47) | SLC7A5SLC1A3SLC1A2PSMB8PSMB5 | |
| SCHEMBL15581542 | 1.00 | SLC7A5 (0.47) | SLC7A5SLC1A3SLC1A2PSMB8PSMB5 | |
| SCHEMBL18257498 | 1.00 | SLC7A5 (0.47) | SLC7A5SLC1A3SLC1A2PSMB8PSMB5 | |
| Hydrochloric Acid SCHEMBL29079421 | 0.98 | SLC7A5 (0.45) | SLC7A5SLC1A3SLC1A2PSMB8PSMB5 | |
| Trichloroacetic Acid SCHEMBL20210932 | 0.89 | SLC7A5 (0.42) | SLC7A5SLC1A3SLC1A2PSMB8PSMB5 | |
| Trifluoroacetic Acid SCHEMBL15634857 | 0.89 | SLC7A5 (0.42) | SLC7A5SLC1A3SLC1A2PSMB8PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113024637-B | Method for preparing carfilzomib by taking water-soluble alkynylamide as condensing agent | 江西师范大学 | 2023-05-16 | — | — | CN | claimed |
| CN-113024637-A | Method for preparing carfilzomib by using water-soluble alkynylamide as condensing agent | 江西师范大学 | 2021-06-25 | — | — | CN | claimed |
| US-10544189-B2 | Process for the preparation of (2S)-N-((S)-1-((S)-4-methyl-1-((R)-2-methyl oxiran-2-yl)-1-oxopentan-2-ylcarbamoyl)-2-phenylethyl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)-4-methylpentanamide | MSN LABORATORIES PRIVATE LIMITED (IN) | 2020-01-28 | — | — | US | claimed |
| US-10301353-B2 | Co-crystal of carfilzomib with maleic acid and process for the preparation of pure carfilzomib | DR. REDDY'S LABORATORIES LIMITED (IN) | 2019-05-28 | — | — | US | claimed |
| US-20180298056-A1 | PROCESS FOR THE PREPARATION OF (2S)-N-((S)-1-((S)-4-METHYL-1-((R)-2-METHYL OXIRAN-2-YL)-1-OXOPENTAN-2-YLCARBAMOYL)-2-PHENYLETHYL)-2-((S)-2-(2-MORPHOLINO ACETAMIDO)-4-PHENYLBUTANAMIDO)-4-METHYLPENTANAMIDE | MSN LABORATORIES PRIVATE LIMITED (IN) | 2018-10-18 | — | — | US | claimed |
| US-20170369528-A1 | CO-CRYSTAL OF CARFILZOMIB WITH MALEIC ACID AND PROCESS FOR THE PREPARATION OF PURE CARFILZOMIB | DR. REDDY'S LABORATORIES LIMITED (IN) | 2017-12-28 | — | — | US | claimed |
| EP-3240575-A1 | CO-CRYSTAL OF CARFILZOMIB WITH MALEIC ACID AND PROCESS FOR THE PREPARATION OF PURE CARFILZOMIB | Dr. Reddy's Laboratories Ltd. (IN) | 2017-11-08 | — | — | EP | claimed |
| WO-2016170544-A1 | PROCESS FOR THE PREPARATION OF (2S)-N-((S)-1-((S)-4-METHYL-1-((R)-2-METHYL OXIRAN-2-YL)-1-OXOPENTAN-2-YLCARBAMOYL)-2-PHENYLETHYL)-2-((S)-2-(2-MORPHOLINO ACETAMIDO)-4-PHENYLBUTANAMIDO)-4-METHYLPENTANAMIDE | MSN LABORATORIES PRIVATE LIMITED (IN) | 2016-10-27 | — | — | WO | claimed |
| WO-2016108204-A1 | CO-CRYSTAL OF CARFILZOMIB WITH MALEIC ACID AND PROCESS FOR THE PREPARATION OF PURE CARFILZOMIB | DR. REDDY'S LABORATORIES LIMITED (IN) | 2016-07-07 | — | — | WO | claimed |
| US-20230357319-A1 | PROTEASOME INHIBITORS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2023-11-09 | — | — | US | disclosed |
| WO-2023209440-A1 | METHOD OF EVALUATING SMALL MOLECULE DISTRIBUTION USING TELLUROPHENE ANALOGUES | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2023-11-02 | — | — | WO | disclosed |
| CN-109641863-B | Intermediate for synthesizing carfilzomib and synthesis of pharmaceutically acceptable salt thereof | 美国安进公司 | 2023-10-20 | — | — | CN | disclosed |
| US-11708341-B2 | Synthesis of (S)-2-amino-4-methyl-((R)-2-methyloxirane-2-yl)-pentan-1-one and pharmaceutically acceptable salts thereof | AMGEN INC. | 2023-07-25 | — | — | US | disclosed |
| US-11708341-B2 | Synthesis of (S)-2-amino-4-methyl-((R)-2-methyloxirane-2-yl)-pentan-1-one and pharmaceutically acceptable salts thereof | AMGEN INC. | 2023-07-25 | — | — | US | disclosed |
| US-7232818-B2 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-7232818-B2 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| WO-2007056464-A1 | COMPOUNDS FOR ENZYME INHIBITION | PROTEOLIX, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105786-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| WO-2005111008-A2 | COMPOUNDS FOR ENZYME INHIBITION | PROTEOLIX, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005105827-A2 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | PROTEOLIX, INC. (US) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544189-B2 | Process for the preparation of (2S)-N-((S)-1-((S)-4-methyl-1-((R)-2-methyl oxiran-2-yl)-1-oxopentan-2-ylcarbamoyl)-2-phenylethyl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)-4-methylpentanamide | OPRL1, PNMT, HTR1A | SLC7A5 2412/4885SLC1A3 1140/4885SLC1A2 521/4885 |
| US-20180298056-A1 | PROCESS FOR THE PREPARATION OF (2S)-N-((S)-1-((S)-4-METHYL-1-((R)-2-METHYL OXIRAN-2-YL)-1-OXOPENTAN-2-YLCARBAMOYL)-2-PHENYLETHYL)-2-((S)-2-(2-MORPHOLINO ACETAMIDO)-4-PHENYLBUTANAMIDO)-4-METHYLPENTANAMIDE | OPRL1, OPRM1, ADRA1D | SLC7A5 2486/4885SLC1A3 1236/4885SLC1A2 610/4885 |
| US-20070105786-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | ANPEP, PSMB1, PSMB3 | SLC7A5 3667/4885SLC1A3 4119/4885SLC1A2 4672/4885 |
| US-20170369528-A1 | CO-CRYSTAL OF CARFILZOMIB WITH MALEIC ACID AND PROCESS FOR THE PREPARATION OF PURE CARFILZOMIB | PRCP, ME1, MAN2B1 | SLC7A5 2519/4885SLC1A3 4496/4885SLC1A2 4713/4885 |
| US-10301353-B2 | Co-crystal of carfilzomib with maleic acid and process for the preparation of pure carfilzomib | PRCP, ME1, MAN2B1 | SLC7A5 2519/4885SLC1A3 4496/4885SLC1A2 4713/4885 |
| US-11708341-B2 | Synthesis of (S)-2-amino-4-methyl-((R)-2-methyloxirane-2-yl)-pentan-1-one and pharmaceutically acceptable salts thereof | EPOR, KDM5A, PSMA5 | SLC7A5 380/4885SLC1A3 2509/4885SLC1A2 3038/4885 |
| US-20230357319-A1 | PROTEASOME INHIBITORS | PSMG3, PSME1, PSMB1 | SLC7A5 3980/4885SLC1A3 4557/4885SLC1A2 4796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.